Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide - PubMed (original) (raw)

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

G E Peoples et al. Proc Natl Acad Sci U S A. 1995.

Abstract

The identification of antigenic peptides presented on the tumor cell surface by HLA class I molecules and recognized by tumor-specific cytotoxic T lymphocytes may lead to a peptide vaccine capable of inducing protective cellular immunity. We demonstrate that both HLA-A2-restricted breast and ovarian tumor-specific cytotoxic T lymphocytes recognize shared antigenic peptides. At least one of these peptides is derived from the oncogene product of HER2/neu, which is overexpressed in 30-40% of all breast and ovarian cancers. T cells sensitized against this nine-amino acid sequence demonstrate significant recognition of HLA-A2+, HER2/neu+ tumors. Since 50% of the tumor-cell population is HLA-A2+ and many different tumors express HER2/neu, this peptide may be widely recognized and have many clinical applications.

PubMed Disclaimer

Similar articles

• The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
  Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ. Peiper M, et al. Eur J Immunol. 1997 May;27(5):1115-23. doi: 10.1002/eji.1830270511. Eur J Immunol. 1997. PMID: 9174600
• In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour.
  Linehan DC, Peoples GE, Hess DT, Summerhayes IC, Parikh AS, Goedegebuure PS, Eberlein TJ. Linehan DC, et al. Surg Oncol. 1995 Feb;4(1):41-9. doi: 10.1016/s0960-7404(10)80030-1. Surg Oncol. 1995. PMID: 7780612
• Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
  Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ. Linehan DC, et al. J Immunol. 1995 Nov 1;155(9):4486-91. J Immunol. 1995. PMID: 7594611
• Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition.
  Correa I, Plunkett T. Correa I, et al. Breast Cancer Res. 2001;3(6):399-403. doi: 10.1186/bcr330. Epub 2001 Sep 20. Breast Cancer Res. 2001. PMID: 11737893 Free PMC article. Review.
• Tumor antigens and markers for breast and ovarian cancers.
  Ghadersohi A, Chitta K, Greco WR, Harvey S, Winston J, Slocum H, Odunsi K, Sood AK. Ghadersohi A, et al. Front Biosci. 2002 Feb 1;7:e48-57. doi: 10.2741/ghader. Front Biosci. 2002. PMID: 11815284 Review.

Cited by

• Creation and characterization of a recombinant mammalian orthoreovirus expressing σ1 fusion proteins encoding human epidermal growth factor receptor 2 peptides.
  Jandick NA, Miller CL. Jandick NA, et al. Virology. 2023 Oct;587:109871. doi: 10.1016/j.virol.2023.109871. Epub 2023 Aug 19. Virology. 2023. PMID: 37634292 Free PMC article.
• Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches.
  Lučić I, Kurtović M, Mlinarić M, Piteša N, Čipak Gašparović A, Sabol M, Milković L. Lučić I, et al. Int J Mol Sci. 2023 Jun 26;24(13):10683. doi: 10.3390/ijms241310683. Int J Mol Sci. 2023. PMID: 37445860 Free PMC article. Review.
• Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity.
  Houlahan KE, Khan A, Greenwald NF, West RB, Angelo M, Curtis C. Houlahan KE, et al. bioRxiv [Preprint]. 2023 Mar 16:2023.03.15.532870. doi: 10.1101/2023.03.15.532870. bioRxiv. 2023. PMID: 36993286 Free PMC article. Updated. Preprint.
• The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions.
  Alrhmoun S, Sennikov S. Alrhmoun S, et al. Cancers (Basel). 2022 Dec 14;14(24):6173. doi: 10.3390/cancers14246173. Cancers (Basel). 2022. PMID: 36551661 Free PMC article. Review.
• Development of the Breast Surgical Oncology Fellowship in the United States.
  Westcott LZ, Jones RC, Fleshman JW Jr. Westcott LZ, et al. Breast J. 2022 May 19;2022:3342910. doi: 10.1155/2022/3342910. eCollection 2022. Breast J. 2022. PMID: 35711884 Free PMC article. Review.

References

1. 1. J Immunol. 1993 Oct 15;151(8):4209-20 - PubMed
2. 1. Nature. 1991 May 23;351(6324):290-6 - PubMed
3. 1. J Immunol. 1993 Nov 15;151(10):5481-91 - PubMed
4. 1. Cancer Res. 1994 Jan 1;54(1):16-20 - PubMed
5. 1. J Immunol. 1994 Mar 1;152(5):2393-400 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal